An observational study in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2017-04-07.
Sponsored by Novartis Pharmaceuticals · Observational
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.
1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.
This study's enrollment of 324 is below the median of 600 across 218 observational studies indexed under Malaria.
Browse Malaria studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the Centers for Disease Control, Atlanta GA.
Exclusion Criteria:
Other: Artemether-lumefantrine
Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start
Time frame: 4 weeks
Adverse event, serious adverse event after artemether-lumefantrine treatment start
Time frame: 4 weeks
Pregnancies after artemether-lumefantrine treatment start
Time frame: Up to delivery
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals